Novavax cuts 2022 revenue guidance in half, stock tanks in after-hours trading
The Maryland biotech company cut its 2022 sales outlook by about 50% and now expects to generate $2 billion to $2.3 billion in revenue this year.
Source link
The Maryland biotech company cut its 2022 sales outlook by about 50% and now expects to generate $2 billion to $2.3 billion in revenue this year.
Source link
